Journal article
Can understanding the neurobiology of body dysmorphic disorder (BDD) inform treatment?
SL Rossell, BJ Harrison, D Castle
Australasian Psychiatry | SAGE PUBLICATIONS LTD | Published : 2015
Abstract
Objectives: We aim to provide a clinically focused review of the neurobiological literature in body dysmorphic disorder (BDD), with a focus on structural and functional neuroimaging. Conclusions: There has been a recent influx of studies examining the underlying neurobiology of BDD using structural and functional neuroimaging methods. Despite obvious symptom similarities with obsessive-compulsive disorder (OCD), no study to date has directly compared the two groups using neuroimaging techniques. Studies have established that there are limbic and visual cortex abnormalities in BDD, in contrast to fronto-striatal differences in OCD. Such data suggests affect or visual training maybe useful in ..
View full abstractGrants
Funding Acknowledgements
David Castle has received grant monies for research from Eli Lilly, Janssen Cilag, Roche, Allergen, Bristol-Myers Squibb, Pfizer, Lundbeck, Astra Zeneca, Hospira; Travel Support and Honoraria for Talks and Consultancy from Eli Lilly, Bristol-Myers Squibb, Astra Zeneca, Lundbeck, Janssen Cilag, Pfizer, Organon, Sanofi-Aventis, Wyeth, Hospira, Servier; and is a current Advisory Board Member for Lu AA21004: Lundbeck; Varenicline: Pfizer; Asenapine: Lundbeck; Bitopertin: Roche Aripiprazole LAI: Lundbeck; Lisdexamfetamine: Shire. He has no stocks or shares in any pharmaceutical company.